Skip to content

Self-hosted, Self-Improving, Federated Everything App — dev management, agent orchestration, persistent mind, digital twin, second brain, and creative pipeline from a single dashboard over Tailscale to port the user into the OS

118 KB
Raw Blame
[
  {
    "rsid": "rs2802292",
    "gene": "FOXO3A",
    "name": "Longevity / FOXO3A",
    "category": "longevity",
    "description": "FOXO3A is one of the most replicated longevity-associated genes. The G allele is linked to exceptional lifespan across multiple populations.",
    "implications": {
      "beneficial": "Carries the longevity-associated G/G genotype. Associated with improved stress resistance and cellular maintenance.",
      "typical": "Heterozygous carrier. Partial longevity association.",
      "concern": "Does not carry the longevity-associated allele."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2229765",
    "gene": "IGF1R",
    "name": "Insulin-like Growth Factor Receptor",
    "category": "longevity",
    "description": "IGF1R variants affect growth factor signaling. Reduced IGF-1 signaling is associated with extended lifespan in model organisms and centenarian studies.",
    "implications": {
      "beneficial": "Genotype associated with favorable IGF-1 signaling for longevity.",
      "typical": "Intermediate IGF-1 receptor activity.",
      "concern": "Standard IGF-1 signaling — no longevity advantage from this variant."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs5882",
    "gene": "CETP",
    "name": "HDL Cholesterol / CETP",
    "category": "longevity",
    "description": "CETP transfers cholesterol between lipoproteins. The Val (G) allele is associated with higher HDL levels and longevity in Ashkenazi centenarian studies.",
    "implications": {
      "beneficial": "Val/Val genotype — associated with higher HDL cholesterol and longevity.",
      "typical": "Heterozygous — intermediate HDL effect.",
      "concern": "Ile/Ile genotype — standard CETP activity."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs12366",
    "gene": "IPMK",
    "name": "Inositol Polyphosphate Multikinase",
    "category": "longevity",
    "description": "IPMK is involved in cellular signaling and nutrient sensing pathways. Variants may influence metabolic longevity pathways.",
    "implications": {
      "beneficial": "Genotype associated with favorable metabolic signaling.",
      "typical": "Intermediate variant — standard metabolic signaling.",
      "concern": "No longevity-associated variant detected."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1042522",
    "gene": "TP53",
    "name": "Tumor Protein p53 (Pro72Arg)",
    "category": "tumor_suppression",
    "description": "TP53 is the guardian of the genome. The Pro72Arg polymorphism affects apoptotic efficiency. Arg (G) induces apoptosis more efficiently, while Pro (C) favors cell cycle arrest and DNA repair.",
    "implications": {
      "beneficial": "Arg/Arg — more efficient apoptotic response to DNA damage.",
      "typical": "Heterozygous — balanced apoptosis and repair capacity.",
      "concern": "Pro/Pro — favors repair over apoptosis, which may affect tumor suppression efficiency."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1799945",
    "gene": "HFE (H63D)",
    "name": "Hereditary Hemochromatosis H63D",
    "category": "iron",
    "description": "H63D is a common HFE variant associated with mild iron overload. Homozygous carriers have moderately increased iron absorption.",
    "implications": {
      "beneficial": "No H63D variant — normal iron regulation.",
      "concern": "Heterozygous carrier — mildly increased iron absorption. Monitor ferritin levels.",
      "major_concern": "Homozygous H63D — moderate hemochromatosis risk. Regular iron panel monitoring recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs1800562",
    "gene": "HFE (C282Y)",
    "name": "Hereditary Hemochromatosis C282Y",
    "category": "iron",
    "description": "C282Y is the primary HFE mutation for hereditary hemochromatosis. Homozygous carriers have significantly increased iron absorption and organ damage risk.",
    "implications": {
      "beneficial": "No C282Y variant — normal iron regulation.",
      "concern": "Heterozygous carrier — mild hemochromatosis risk. Compound heterozygosity with H63D increases risk.",
      "major_concern": "Homozygous C282Y — high hereditary hemochromatosis risk. Regular phlebotomy and monitoring essential."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs1801133",
    "gene": "MTHFR",
    "name": "MTHFR C677T",
    "category": "methylation",
    "description": "MTHFR C677T affects folate metabolism and homocysteine levels. The T variant reduces enzyme activity, impacting methylation capacity.",
    "implications": {
      "beneficial": "C/C — normal MTHFR enzyme activity (~100%). Standard folate metabolism.",
      "concern": "C/T heterozygous — ~65% enzyme activity. Consider methylfolate supplementation.",
      "major_concern": "T/T homozygous — ~30% enzyme activity. Elevated homocysteine risk. Methylfolate supplementation recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs1801131",
    "gene": "MTHFR",
    "name": "MTHFR A1298C",
    "category": "methylation",
    "description": "MTHFR A1298C is a second common variant affecting methylation. Less impactful alone than C677T, but compound heterozygosity (one copy of each) can significantly reduce function.",
    "implications": {
      "beneficial": "T/T — normal MTHFR activity at this position.",
      "concern": "Heterozygous — mildly reduced activity. Check for compound heterozygosity with C677T.",
      "major_concern": "Homozygous variant — reduced activity at both MTHFR positions increases methylation impact."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs4680",
    "gene": "COMT",
    "name": "COMT Val158Met",
    "category": "methylation",
    "description": "COMT metabolizes catecholamines (dopamine, norepinephrine) in the prefrontal cortex. Val (G) = fast breakdown (\"Warrior\" — stress-resilient), Met (A) = slow breakdown (\"Worrier\" — better focus in calm). Neither is inherently better — context matters.",
    "implications": {
      "beneficial": "A/G heterozygous — balanced COMT activity. Often considered optimal for both focus and stress resilience.",
      "typical": "G/G Val/Val — fast COMT. Lower dopamine baseline. Better stress resilience, may need more stimulation for focus.",
      "concern": "A/A Met/Met — slow COMT. Higher dopamine baseline. Better focus under calm conditions, but more stress-sensitive."
    },
    "rules": [
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs819147",
    "gene": "AHCY",
    "name": "S-Adenosylhomocysteine Hydrolase",
    "category": "methylation",
    "description": "AHCY converts S-adenosylhomocysteine to homocysteine in the methylation cycle. Variants can affect methylation efficiency and homocysteine clearance.",
    "implications": {
      "beneficial": "Normal AHCY function — efficient methylation cycle turnover.",
      "typical": "Heterozygous — mildly altered AHCY activity.",
      "concern": "Homozygous variant — may affect methylation cycle efficiency."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs73598374",
    "gene": "ADA",
    "name": "Caffeine / Adenosine Processing",
    "category": "caffeine",
    "description": "ADA (adenosine deaminase) breaks down adenosine, the molecule caffeine blocks. Variants affect caffeine sensitivity and sleep quality after caffeine consumption.",
    "implications": {
      "beneficial": "C/C — normal adenosine processing. Standard caffeine response.",
      "concern": "C/T — altered adenosine metabolism. May be more sensitive to caffeine effects on sleep.",
      "major_concern": "T/T — significantly altered adenosine processing. Likely high caffeine sensitivity."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs3745274",
    "gene": "CYP2B6",
    "name": "Drug Metabolism / CYP2B6",
    "category": "detox",
    "description": "CYP2B6 metabolizes many drugs including efavirenz, bupropion, and cyclophosphamide. Variants affect metabolism speed and drug response.",
    "implications": {
      "beneficial": "G/G — normal (extensive) metabolizer. Standard drug metabolism.",
      "typical": "G/T — intermediate metabolizer. May need dose adjustments for some medications.",
      "concern": "T/T — poor metabolizer. Significantly altered drug metabolism. Pharmacogenomic testing recommended before certain medications."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4880",
    "gene": "SOD2",
    "name": "Superoxide Dismutase / Oxidative Stress",
    "category": "detox",
    "description": "SOD2 (MnSOD) neutralizes superoxide radicals in mitochondria. The Ala16Val polymorphism affects mitochondrial targeting and antioxidant capacity.",
    "implications": {
      "beneficial": "A/G heterozygous — balanced SOD2 activity. Heterozygote advantage documented in some studies.",
      "typical": "G/G Ala/Ala — efficient mitochondrial import. Good baseline antioxidant capacity.",
      "concern": "A/A Val/Val — less efficient mitochondrial targeting. May benefit from additional antioxidant support."
    },
    "rules": [
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1800795",
    "gene": "IL-6",
    "name": "Interleukin-6 Inflammation",
    "category": "inflammation",
    "description": "IL-6 is a key inflammatory cytokine. The -174 G/C promoter polymorphism affects IL-6 expression levels and systemic inflammation.",
    "implications": {
      "beneficial": "G/G — lower baseline IL-6 levels. Reduced systemic inflammation.",
      "typical": "G/C — intermediate IL-6 expression.",
      "concern": "C/C — higher baseline IL-6 levels. Associated with increased inflammatory response and cardiovascular risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/C",
          "C/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1800629",
    "gene": "TNF-alpha",
    "name": "TNF-alpha Inflammatory Response",
    "category": "inflammation",
    "description": "TNF-alpha is a master regulator of the inflammatory cascade. The -308 G>A promoter variant increases TNF-alpha production, raising risk for autoimmune and inflammatory conditions.",
    "implications": {
      "beneficial": "G/G — normal TNF-alpha expression. Standard inflammatory baseline.",
      "typical": "G/A — moderately elevated TNF-alpha. Slightly increased inflammatory tendency.",
      "concern": "A/A — significantly elevated TNF-alpha production. Higher risk for rheumatoid arthritis, inflammatory bowel disease, and other autoimmune conditions."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs6025",
    "gene": "F5 (Factor V)",
    "name": "Factor V Leiden Thrombophilia",
    "category": "cardiovascular",
    "description": "Factor V Leiden is the most common inherited thrombophilia. The variant makes Factor V resistant to inactivation by Protein C, increasing venous clot risk 5-80x depending on zygosity.",
    "implications": {
      "beneficial": "C/C — no Factor V Leiden variant. Normal clotting regulation.",
      "concern": "C/T — heterozygous carrier. 5-10x increased risk of venous thromboembolism. Discuss with physician before surgery, hormonal contraceptives, or long flights.",
      "major_concern": "T/T — homozygous Factor V Leiden. 50-100x increased clotting risk. Anticoagulation management strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs1333049",
    "gene": "9p21.3",
    "name": "Coronary Artery Disease Risk (9p21)",
    "category": "cardiovascular",
    "description": "The 9p21.3 locus is the strongest common genetic risk factor for coronary artery disease, replicated in >100,000 individuals across multiple ethnicities. It affects vascular cell proliferation near CDKN2A/B tumor suppressors.",
    "implications": {
      "beneficial": "G/G — lower genetic risk for coronary artery disease.",
      "typical": "C/G — average population risk. One copy of risk allele.",
      "concern": "C/C — elevated genetic risk (~1.6x) for coronary artery disease. Extra emphasis on modifiable risk factors (diet, exercise, lipids)."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs10455872",
    "gene": "LPA",
    "name": "Lipoprotein(a) Levels",
    "category": "cardiovascular",
    "description": "Lipoprotein(a) is a causal, independent cardiovascular risk factor not lowered by statins. This LPA variant strongly predicts elevated Lp(a) levels. High Lp(a) increases risk of heart attack, stroke, and aortic stenosis.",
    "implications": {
      "beneficial": "A/A — predicted normal Lp(a) levels.",
      "concern": "A/G — likely elevated Lp(a). Request a blood Lp(a) measurement to confirm. Consider PCSK9 inhibitors or emerging therapies if confirmed high.",
      "major_concern": "G/G — strongly elevated Lp(a) predicted. High cardiovascular risk independent of LDL. Lp(a) blood test and cardiology consultation recommended."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs1799963",
    "gene": "F2 (Prothrombin)",
    "name": "Prothrombin G20210A Thrombophilia",
    "category": "cardiovascular",
    "description": "The prothrombin G20210A mutation increases prothrombin production, raising venous thromboembolism risk 2-5x. Second most common inherited thrombophilia after Factor V Leiden.",
    "implications": {
      "beneficial": "G/G — normal prothrombin levels. No inherited thrombophilia from this variant.",
      "concern": "G/A — heterozygous carrier. ~3x increased venous clot risk. Combined with Factor V Leiden or oral contraceptives, risk compounds significantly.",
      "major_concern": "A/A — homozygous variant. Substantially elevated clotting risk. Hematology consultation recommended."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs2228570",
    "gene": "VDR",
    "name": "Vitamin D Receptor (FokI)",
    "category": "nutrient",
    "description": "The VDR FokI polymorphism affects Vitamin D receptor length and activity. The shorter \"F\" form (T allele on + strand) is more transcriptionally active, influencing calcium absorption, bone density, and immune function.",
    "implications": {
      "beneficial": "T/T — more active VDR. Better vitamin D utilization at a given blood level.",
      "typical": "C/T — intermediate VDR activity.",
      "concern": "C/C — less active VDR. May require higher vitamin D levels to achieve the same biological effect. Consider testing 25(OH)D levels."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs7501331",
    "gene": "BCMO1",
    "name": "Beta-Carotene to Vitamin A Conversion",
    "category": "nutrient",
    "description": "BCMO1 converts beta-carotene (from plants) into retinal (active Vitamin A). Variants reduce conversion efficiency by 32-69%, meaning plant-based beta-carotene may not meet Vitamin A needs.",
    "implications": {
      "beneficial": "C/C — normal beta-carotene conversion. Plant sources can meet Vitamin A needs.",
      "concern": "C/T — ~32% reduced conversion. May need more preformed Vitamin A (retinol) from animal sources or supplements.",
      "major_concern": "T/T — ~69% reduced conversion. Significantly impaired beta-carotene utilization. Preformed Vitamin A sources recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs602662",
    "gene": "FUT2",
    "name": "Vitamin B12 Absorption (Secretor Status)",
    "category": "nutrient",
    "description": "FUT2 determines \"secretor status\" — whether you secrete blood type antigens into mucus and saliva. Non-secretors have altered gut microbiome composition and reduced Vitamin B12 absorption.",
    "implications": {
      "beneficial": "G/G — secretor. Normal B12 absorption and gut microbiome interaction.",
      "typical": "A/G — secretor (one functional copy sufficient). Generally adequate B12 absorption.",
      "concern": "A/A — non-secretor (~20% of population). Reduced B12 absorption. Monitor B12 levels, especially on plant-based diets. Also associated with resistance to norovirus."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4588",
    "gene": "GC (VDBP)",
    "name": "Vitamin D Binding Protein",
    "category": "nutrient",
    "description": "GC encodes the Vitamin D binding protein that transports vitamin D in blood. Variants affect circulating 25(OH)D levels and bioavailability. This is one of the strongest genetic determinants of vitamin D status.",
    "implications": {
      "beneficial": "C/C — normal VDBP function. Standard vitamin D transport and bioavailability.",
      "typical": "A/C — intermediate effect on vitamin D levels.",
      "concern": "A/A — associated with lower circulating 25(OH)D levels. May need higher supplementation doses to achieve optimal vitamin D status."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs762551",
    "gene": "CYP1A2",
    "name": "Caffeine Metabolism Speed",
    "category": "caffeine",
    "description": "CYP1A2 is the primary liver enzyme that metabolizes caffeine. This is the classic \"fast vs slow caffeine metabolizer\" SNP. Fast metabolizers clear caffeine quickly; slow metabolizers experience prolonged stimulation and higher cardiovascular risk from heavy coffee consumption.",
    "implications": {
      "beneficial": "A/A — fast metabolizer. Caffeine is cleared quickly. Moderate coffee consumption may even be cardioprotective.",
      "typical": "A/C — intermediate metabolizer. Moderate caffeine tolerance.",
      "concern": "C/C — slow metabolizer. Caffeine lingers ~4x longer. Associated with increased heart attack risk from heavy coffee consumption (>3 cups/day). Consider limiting intake, especially afternoon and evening."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4244285",
    "gene": "CYP2C19",
    "name": "Drug Metabolism / CYP2C19",
    "category": "detox",
    "description": "CYP2C19 metabolizes proton pump inhibitors (omeprazole), antidepressants (citalopram), and antiplatelet drugs (clopidogrel). Poor metabolizers may not activate clopidogrel, risking treatment failure after cardiac stents.",
    "implications": {
      "beneficial": "G/G — normal (extensive) metabolizer. Standard drug activation and clearance.",
      "typical": "G/A — intermediate metabolizer. Some drugs may need dose adjustment.",
      "concern": "A/A — poor metabolizer. Clopidogrel may be ineffective. PPIs may accumulate. FDA recommends alternative antiplatelet therapy for CYP2C19 poor metabolizers with cardiac stents."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1800566",
    "gene": "NQO1",
    "name": "Quinone Detoxification (NQO1)",
    "category": "detox",
    "description": "NQO1 detoxifies quinones from diet and environment, preventing oxidative DNA damage. The C609T variant eliminates enzyme activity, reducing protection against benzene toxicity and certain chemotherapy metabolism.",
    "implications": {
      "beneficial": "C/C — full NQO1 activity. Normal quinone detoxification and benzene protection.",
      "typical": "C/T — ~50% enzyme activity. Mildly reduced detoxification capacity.",
      "concern": "T/T — no functional NQO1 enzyme. Increased sensitivity to benzene exposure and oxidative stress. Avoid unnecessary chemical exposures."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs6265",
    "gene": "BDNF",
    "name": "Brain-Derived Neurotrophic Factor (Val66Met)",
    "category": "cognitive",
    "description": "BDNF is critical for neuroplasticity, memory formation, and mood regulation. The Val66Met polymorphism affects activity-dependent BDNF secretion in the brain. Met carriers have reduced hippocampal volume and altered stress response.",
    "implications": {
      "beneficial": "G/G (Val/Val) — normal activity-dependent BDNF secretion. Standard neuroplasticity and memory consolidation.",
      "typical": "A/G (Val/Met) — reduced activity-dependent secretion (~25%). May benefit from regular exercise, which strongly upregulates BDNF.",
      "concern": "A/A (Met/Met) — significantly reduced BDNF secretion. Associated with smaller hippocampal volume, altered stress response, and increased depression susceptibility. Exercise is particularly beneficial for this genotype."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs429358",
    "gene": "APOE",
    "name": "APOE ε4 Alzheimer's Risk (rs429358)",
    "category": "cognitive_decline",
    "description": "APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease. The ε4 allele (T→C at rs429358) impairs amyloid-beta clearance and reduces cerebral glucose metabolism. One copy increases risk ~3x; two copies increase risk ~12x. This SNP combines with rs7412 (ε2) to determine your full APOE haplotype (ε2/ε3/ε4) — see the composite APOE Haplotype marker for combined interpretation.",
    "implications": {
      "beneficial": "T/T — no ε4 allele. Lower baseline Alzheimer's risk from APOE. Check rs7412 for possible ε2 protective status.",
      "concern": "C/T — one ε4 allele. ~3x increased Alzheimer's risk. Prioritize neuroprotective lifestyle: regular cardiovascular exercise, sleep optimization (7-9 hrs), omega-3/DHA (1-2g daily), Mediterranean diet, creatine monohydrate (5g daily for brain energy), and cognitive engagement. Check rs7412 — if also C/T, you may carry the ε2/ε4 combination.",
      "major_concern": "C/C — two ε4 alleles (ε4/ε4). ~12x increased Alzheimer's risk. Earliest average onset among APOE genotypes. Aggressive neuroprotective strategy strongly recommended: cardiovascular exercise (150+ min/week), sleep optimization, omega-3/DHA, Mediterranean diet, blood pressure management, metabolic health monitoring, creatine supplementation, and regular cognitive screening starting mid-40s."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs7412",
    "gene": "APOE",
    "name": "APOE ε2 Protective Variant (rs7412)",
    "category": "cognitive_decline",
    "description": "APOE ε2 is the protective counterpart to ε4. The ε2 allele (C→T at rs7412) is associated with enhanced amyloid-beta clearance and ~40% reduced Alzheimer's risk. This SNP combines with rs429358 (ε4) to determine your full APOE haplotype — see the composite APOE Haplotype marker for combined interpretation.",
    "implications": {
      "beneficial": "T/T — ε2/ε2. Strongest APOE-mediated neuroprotection. Significantly reduced Alzheimer's risk (~0.6x baseline). Note: rare association with type III hyperlipoproteinemia — monitor lipid panel.",
      "typical": "C/T — one ε2 allele. ~40% reduced Alzheimer's risk compared to ε3/ε3. Check rs429358 — if also C/T, you carry ε2/ε4 (mixed risk/protection).",
      "concern": "C/C — no ε2 protective allele. Alzheimer's risk determined primarily by rs429358 ε4 status."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3865444",
    "gene": "CD33",
    "name": "CD33 Microglial Clearance",
    "category": "cognitive_decline",
    "description": "CD33 is expressed on microglia and regulates amyloid-beta phagocytosis. The A allele reduces CD33 surface expression, enhancing microglial clearance of amyloid plaques. Replicated across multiple GWAS for Alzheimer's risk.",
    "implications": {
      "beneficial": "A/A — reduced CD33 expression. Enhanced microglial amyloid clearance. Lower Alzheimer's risk.",
      "typical": "A/C — intermediate CD33 levels. Moderate clearance capacity.",
      "concern": "C/C — higher CD33 expression. Reduced amyloid clearance by microglia."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3764650",
    "gene": "ABCA7",
    "name": "ABCA7 Lipid Transport & Amyloid",
    "category": "cognitive_decline",
    "description": "ABCA7 is involved in lipid transport and amyloid precursor protein processing. Loss-of-function variants increase Alzheimer's risk ~1.8x, particularly in African-ancestry populations where the effect is stronger.",
    "implications": {
      "beneficial": "G/G — normal ABCA7 function. Standard lipid transport and amyloid processing.",
      "typical": "G/T — one risk allele. Mildly elevated Alzheimer's risk.",
      "concern": "T/T — reduced ABCA7 function. ~1.8x increased Alzheimer's risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs6656401",
    "gene": "CR1",
    "name": "Complement Receptor 1 (Neuroinflammation)",
    "category": "cognitive_decline",
    "description": "CR1 encodes complement receptor 1, part of the innate immune system. The A allele is associated with increased amyloid-beta deposition and neuroinflammation, contributing to Alzheimer's risk (~1.2x per allele).",
    "implications": {
      "beneficial": "G/G — standard CR1 expression. Normal complement-mediated clearance.",
      "typical": "A/G — one risk allele. Slightly elevated neuroinflammation risk.",
      "concern": "A/A — elevated CR1 risk. Associated with increased amyloid burden and neuroinflammation."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs11136000",
    "gene": "CLU",
    "name": "Clusterin (Apolipoprotein J)",
    "category": "cognitive_decline",
    "description": "CLU (clusterin/apolipoprotein J) is a chaperone protein that binds amyloid-beta and facilitates its clearance across the blood-brain barrier. The T allele is protective, associated with better amyloid clearance.",
    "implications": {
      "beneficial": "T/T — protective genotype. Enhanced clusterin-mediated amyloid clearance.",
      "typical": "C/T — intermediate effect. Standard clusterin function.",
      "concern": "C/C — reduced clusterin efficiency. Mildly elevated amyloid accumulation risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs744373",
    "gene": "BIN1",
    "name": "BIN1 Tau & Synaptic Function",
    "category": "cognitive_decline",
    "description": "BIN1 (bridging integrator 1) is the second strongest Alzheimer's risk locus after APOE. It's involved in tau pathology, synaptic vesicle recycling, and endocytosis. The C allele increases risk ~1.2x per copy.",
    "implications": {
      "beneficial": "T/T — lower BIN1-mediated Alzheimer's risk. Normal synaptic function.",
      "typical": "C/T — one risk allele. Slightly elevated risk.",
      "concern": "C/C — elevated BIN1 risk. Associated with increased tau pathology and synaptic dysfunction."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs9349407",
    "gene": "PICALM",
    "name": "PICALM Endocytic Clearance",
    "category": "cognitive_decline",
    "description": "PICALM mediates clathrin-mediated endocytosis and amyloid-beta clearance across the blood-brain barrier. Variants affect the efficiency of cellular waste removal in the brain.",
    "implications": {
      "beneficial": "C/C — efficient PICALM function. Better endocytic clearance of amyloid.",
      "typical": "C/G — intermediate clearance capacity.",
      "concern": "G/G — reduced PICALM efficiency. Impaired endocytic amyloid clearance."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3851179",
    "gene": "PICALM",
    "name": "PICALM Protective Variant",
    "category": "cognitive_decline",
    "description": "This PICALM variant is independently protective against Alzheimer's. The A allele enhances autophagy and tau clearance, reducing accumulation of toxic protein aggregates.",
    "implications": {
      "beneficial": "A/A — enhanced autophagy and tau clearance. Protective against Alzheimer's.",
      "typical": "A/G — intermediate protective effect.",
      "concern": "G/G — standard PICALM autophagy function. No additional protection."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs10948363",
    "gene": "CD2AP",
    "name": "CD2AP Blood-Brain Barrier Integrity",
    "category": "cognitive_decline",
    "description": "CD2AP maintains blood-brain barrier integrity and supports synaptic function. Variants are associated with Alzheimer's risk through impaired BBB function and increased neuroinflammation.",
    "implications": {
      "beneficial": "A/A — normal CD2AP function. Intact blood-brain barrier support.",
      "typical": "A/G — intermediate BBB risk.",
      "concern": "G/G — reduced CD2AP function. Associated with BBB dysfunction and elevated Alzheimer's risk."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs983392",
    "gene": "MS4A6A",
    "name": "MS4A6A Microglial Activation",
    "category": "cognitive_decline",
    "description": "MS4A6A is part of the membrane-spanning 4A gene cluster expressed in myeloid cells. Variants affect microglial activation patterns and soluble TREM2 levels, both relevant to Alzheimer's neuroinflammation.",
    "implications": {
      "beneficial": "A/A — protective microglial activation pattern. Higher soluble TREM2.",
      "typical": "A/G — intermediate microglial function.",
      "concern": "G/G — altered microglial activation. Lower soluble TREM2 associated with increased neuroinflammation."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1801260",
    "gene": "CLOCK",
    "name": "Circadian Clock Gene",
    "category": "sleep",
    "description": "CLOCK is a core circadian rhythm gene. The 3111T>C variant is associated with evening chronotype preference, later sleep onset, shorter sleep duration, and higher resistance to sleep deprivation.",
    "implications": {
      "beneficial": "T/T — standard circadian rhythm. Typical sleep-wake preferences.",
      "typical": "T/C — mild evening tendency. Slightly delayed sleep preference.",
      "concern": "C/C — strong evening chronotype. Delayed sleep phase, reduced sleep duration. May struggle with early schedules. Melatonin timing and light exposure management may help."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "T/C",
          "C/T"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs57875989",
    "gene": "DEC2/BHLHE41",
    "name": "Short Sleep Gene",
    "category": "sleep",
    "description": "DEC2 (BHLHE41) regulates sleep duration. The rare \"short sleeper\" mutation allows healthy function on 4-6 hours of sleep without cognitive impairment. Extremely rare (~1% of population).",
    "implications": {
      "beneficial": "Carrier of short-sleep variant — may genuinely require less sleep without health consequences.",
      "typical": "No short-sleep variant — standard 7-9 hour sleep requirement for optimal health."
    },
    "rules": [
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      }
    ]
  },
  {
    "rsid": "rs35333999",
    "gene": "PER2",
    "name": "Period Circadian Clock 2",
    "category": "sleep",
    "description": "PER2 is a core circadian clock gene that drives the negative feedback loop controlling ~24-hour rhythms. Variants affect morning/evening preference and sleep timing. PER2 mutations cause Familial Advanced Sleep Phase Syndrome (FASPS) in severe cases.",
    "implications": {
      "beneficial": "C/C — standard PER2 function. Normal circadian period length.",
      "typical": "C/T — mildly shifted circadian timing. May trend toward earlier or later sleep phase depending on other clock genes.",
      "concern": "T/T — altered PER2 function. More pronounced chronotype shift. May benefit from timed light exposure and consistent sleep-wake scheduling."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2287161",
    "gene": "CRY1",
    "name": "Cryptochrome Circadian Clock 1",
    "category": "sleep",
    "description": "CRY1 is a key repressor in the circadian feedback loop. A gain-of-function variant lengthens the circadian period, strongly associated with Delayed Sleep Phase Disorder (DSPD). Carriers naturally drift toward later sleep-wake times.",
    "implications": {
      "beneficial": "C/C — standard CRY1 function. Normal circadian period (~24 hours).",
      "typical": "C/G — one variant allele. Mildly extended circadian period. Slight evening tendency.",
      "concern": "G/G — extended circadian period. Strong evening chronotype and delayed sleep onset. Associated with DSPD. Timed morning light exposure and evening light restriction are particularly effective."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1815739",
    "gene": "ACTN3",
    "name": "Muscle Fiber Type (Sprint vs Endurance)",
    "category": "athletic",
    "description": "ACTN3 encodes alpha-actinin-3, a protein found exclusively in fast-twitch muscle fibers. The R577X polymorphism determines whether you produce it. ~18% of people worldwide are X/X (no alpha-actinin-3), favoring endurance over sprint/power.",
    "implications": {
      "beneficial": "C/C (R/R) — alpha-actinin-3 present. Fast-twitch muscle fibers fully functional. Advantage in sprint, power, and strength activities.",
      "typical": "C/T (R/X) — one functional copy. Mixed fiber profile. Versatile across power and endurance.",
      "concern": "T/T (X/X) — no alpha-actinin-3. Fast-twitch fibers remodeled toward slow-twitch. Natural endurance advantage but reduced peak power output. Not pathological — many elite endurance athletes carry this genotype."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4341",
    "gene": "ACE",
    "name": "ACE Insertion/Deletion (Endurance)",
    "category": "athletic",
    "description": "The ACE I/D polymorphism affects angiotensin-converting enzyme levels. The I allele (lower ACE) is associated with endurance performance and altitude adaptation. The D allele (higher ACE) is associated with power/sprint performance.",
    "implications": {
      "beneficial": "G/G — associated with endurance-favorable ACE levels.",
      "typical": "A/G — mixed profile. Balanced endurance and power potential.",
      "concern": "A/A — associated with higher ACE activity. Power-oriented physiology, but also linked to higher blood pressure and cardiovascular strain during prolonged endurance exercise."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1805007",
    "gene": "MC1R",
    "name": "Melanin Type / UV Sensitivity",
    "category": "skin",
    "description": "MC1R controls the switch between eumelanin (dark, UV-protective) and pheomelanin (red/yellow, UV-sensitizing). This R151C variant is strongly associated with red hair, fair skin, freckling, and increased melanoma risk.",
    "implications": {
      "beneficial": "C/C — normal MC1R function. Standard eumelanin production and UV protection.",
      "typical": "C/T — one variant copy. Mildly increased UV sensitivity and freckling tendency.",
      "concern": "T/T — strongly reduced MC1R function. Fair skin, high UV sensitivity, 2-4x melanoma risk. Rigorous sun protection essential."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs9939609",
    "gene": "FTO",
    "name": "Fat Mass & Obesity Associated Gene",
    "category": "longevity",
    "description": "FTO is the strongest common genetic contributor to obesity risk. The A allele increases appetite, reduces satiety signaling, and is associated with higher BMI. Each A allele adds ~1.5kg average weight. Effect is substantially modifiable by physical activity.",
    "implications": {
      "beneficial": "T/T — lower genetic obesity risk. Standard appetite regulation.",
      "typical": "A/T — one risk allele. Modestly increased obesity risk (~1.2x). Regular physical activity largely negates the effect.",
      "concern": "A/A — two risk alleles (~1.7x obesity risk). Reduced satiety signaling. Physically active A/A carriers show almost no excess risk — exercise is the most effective countermeasure for this genotype."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/T",
          "T/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs7903146",
    "gene": "TCF7L2",
    "name": "Type 2 Diabetes Risk (TCF7L2)",
    "category": "diabetes",
    "description": "TCF7L2 is the strongest common genetic risk factor for type 2 diabetes, replicated across all ethnicities. The T allele impairs insulin secretion from pancreatic beta cells via altered Wnt signaling. Each T allele increases T2D risk ~1.4x.",
    "implications": {
      "beneficial": "C/C — no risk alleles. Standard insulin secretion and beta cell function.",
      "typical": "C/T — one risk allele. ~1.4x increased T2D risk. Maintain healthy weight and monitor fasting glucose.",
      "concern": "T/T — two risk alleles. ~2x increased T2D risk. Impaired insulin secretion. Regular HbA1c monitoring, weight management, and exercise strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs5219",
    "gene": "KCNJ11",
    "name": "Potassium Channel / Insulin Secretion (E23K)",
    "category": "diabetes",
    "description": "KCNJ11 encodes the Kir6.2 subunit of the ATP-sensitive potassium channel in pancreatic beta cells controlling insulin release. The T allele (Lys23) reduces insulin secretion efficiency.",
    "implications": {
      "beneficial": "C/C (Glu/Glu) — normal potassium channel function. Standard insulin secretion.",
      "typical": "C/T — heterozygous. Mildly reduced insulin release efficiency.",
      "concern": "T/T (Lys/Lys) — impaired potassium channel regulation. Reduced insulin secretion. ~1.3x T2D risk. Monitor glucose levels."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs13266634",
    "gene": "SLC30A8",
    "name": "Zinc Transporter 8 / Islet Function",
    "category": "diabetes",
    "description": "SLC30A8 encodes a zinc transporter critical for insulin crystallization and storage in pancreatic beta cells. The C allele (Arg325) increases T2D risk ~1.15x per allele. Loss-of-function variants are protective, making this a drug target.",
    "implications": {
      "beneficial": "T/T (Trp/Trp) — protective variant. Enhanced beta cell function.",
      "typical": "C/T — one risk allele. Standard islet zinc transport.",
      "concern": "C/C (Arg/Arg) — reduced zinc transport efficiency. Mildly increased T2D risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4988235",
    "gene": "MCM6 (LCT regulatory)",
    "name": "Lactase Persistence / Lactose Tolerance",
    "category": "gut_health",
    "description": "This regulatory SNP upstream of the LCT gene determines whether lactase production continues into adulthood. The T allele maintains lactase expression. C/C leads to lactase non-persistence (lactose intolerance). One of the strongest signals of recent human natural selection.",
    "implications": {
      "beneficial": "T/T — lactase persistent. Full lactose digestion into adulthood.",
      "typical": "C/T — heterozygous. Usually sufficient lactase for moderate dairy consumption.",
      "concern": "C/C — lactase non-persistent. Reduced or absent lactase in adulthood. Likely lactose intolerant. Consider lactase supplements or dairy alternatives."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2187668",
    "gene": "HLA-DQA1 (DQ2.5)",
    "name": "Celiac Disease Risk (HLA-DQ2.5)",
    "category": "gut_health",
    "description": "HLA-DQ2.5 is carried by ~90% of celiac disease patients. Homozygous carriers have the highest celiac risk (~1 in 10 lifetime). Necessary but not sufficient — ~30% of the general population carries DQ2.5 but only ~3% develop celiac.",
    "implications": {
      "beneficial": "T/T — does not carry the DQ2.5 risk haplotype. Lower celiac risk.",
      "typical": "C/T — heterozygous DQ2.5 carrier. Celiac possible but most carriers never develop it. If symptomatic, consider tTG-IgA antibody testing.",
      "concern": "C/C — homozygous DQ2.5 carrier. Highest genetic celiac risk (~5-10% lifetime). Screen with tTG-IgA if GI symptoms, iron deficiency, or family history."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2476601",
    "gene": "PTPN22",
    "name": "Autoimmune Susceptibility (R620W)",
    "category": "autoimmune",
    "description": "PTPN22 R620W is one of the strongest non-HLA autoimmune risk variants, replicated across type 1 diabetes, rheumatoid arthritis, lupus, Graves disease, and other autoimmune conditions. The A allele alters T-cell and B-cell receptor signaling thresholds.",
    "implications": {
      "beneficial": "G/G — normal PTPN22 function. Standard immune self-tolerance.",
      "concern": "G/A — heterozygous carrier. ~1.5-2x increased risk across multiple autoimmune diseases. Monitor for symptoms.",
      "major_concern": "A/A — homozygous variant. Substantially increased autoimmune risk. Be vigilant for thyroid, joint, or systemic autoimmune symptoms."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs3184504",
    "gene": "SH2B3",
    "name": "Immune & Cardiovascular Cross-Risk (SH2B3)",
    "category": "autoimmune",
    "description": "SH2B3 (LNK) regulates signaling in immune and hematopoietic cells. The T allele is associated with increased risk for celiac disease, type 1 diabetes, and cardiovascular disease simultaneously — a cross-domain risk marker. Highly replicated in GWAS.",
    "implications": {
      "beneficial": "C/C — normal SH2B3 signaling. Standard immune and cardiovascular risk baseline.",
      "typical": "C/T — one risk allele. Mildly elevated autoimmune and cardiovascular risk.",
      "concern": "T/T — two risk alleles. Elevated risk across celiac, type 1 diabetes, and cardiovascular disease."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs965513",
    "gene": "FOXE1",
    "name": "Thyroid Disease Susceptibility (FOXE1)",
    "category": "thyroid",
    "description": "FOXE1 (TTF-2) is a thyroid transcription factor essential for thyroid development. This variant is the strongest common genetic risk factor for both hypothyroidism and thyroid cancer. The A allele increases risk ~1.4x per copy.",
    "implications": {
      "beneficial": "G/G — lower genetic risk for thyroid disease.",
      "typical": "A/G — one risk allele. Mildly elevated thyroid disease susceptibility.",
      "concern": "A/A — two risk alleles. Elevated risk for hypothyroidism and thyroid cancer. Regular TSH screening recommended."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs225014",
    "gene": "DIO2",
    "name": "Thyroid Hormone Activation (Thr92Ala)",
    "category": "thyroid",
    "description": "DIO2 encodes type 2 deiodinase, converting T4 (inactive) to T3 (active thyroid hormone) in brain and muscle. The Ala92 variant reduces local T3 production. Some patients report persistent hypothyroid symptoms despite normal TSH.",
    "implications": {
      "beneficial": "C/C (Thr/Thr) — normal DIO2 activity. Efficient T4-to-T3 conversion.",
      "typical": "C/T — one Ala allele. Mildly reduced tissue T3 levels. Some hypothyroid patients benefit from combination T4+T3 therapy.",
      "concern": "T/T (Ala/Ala) — reduced local T3 production. May experience hypothyroid symptoms despite normal TSH. Discuss T3/T4 ratio with endocrinologist."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1061170",
    "gene": "CFH",
    "name": "Age-Related Macular Degeneration Risk (CFH Y402H)",
    "category": "eye_health",
    "description": "Complement factor H regulates the alternative complement pathway in the retina. Y402H is the strongest genetic risk factor for age-related macular degeneration (AMD), increasing risk ~2.5x per allele. One of the first GWAS successes.",
    "implications": {
      "beneficial": "T/T (Tyr/Tyr) — normal complement regulation. Lower AMD risk.",
      "concern": "T/C — one risk allele. ~2.5x increased AMD risk. Regular eye exams after age 50. Consider lutein/zeaxanthin supplementation.",
      "major_concern": "C/C (His/His) — ~6x increased AMD risk. Prioritize retinal screening, AREDS2 formula (lutein/zeaxanthin), smoking cessation, and UV protection."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "T/C",
          "C/T"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs10490924",
    "gene": "ARMS2/HTRA1",
    "name": "Macular Degeneration Risk (ARMS2)",
    "category": "eye_health",
    "description": "ARMS2/HTRA1 on chromosome 10q26 is the second major AMD locus after CFH. The T allele increases risk ~2.7x per copy. Together with CFH, these two loci explain the majority of genetic AMD risk.",
    "implications": {
      "beneficial": "G/G — lower ARMS2-mediated AMD risk.",
      "concern": "G/T — one risk allele. ~2.7x increased AMD risk. Combined with CFH genotype for AMD risk stratification.",
      "major_concern": "T/T — ~7x increased AMD risk from this locus alone. Regular retinal screening strongly recommended. AREDS2 supplementation and UV protection."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs6311",
    "gene": "HTR2A",
    "name": "Serotonin Receptor 2A (-1438 A/G)",
    "category": "mental_health",
    "description": "HTR2A encodes the serotonin 2A receptor, a primary target of many antidepressants and antipsychotics. The -1438 A/G promoter variant affects receptor expression levels and antidepressant response.",
    "implications": {
      "beneficial": "G/G — standard HTR2A expression. Typical serotonin receptor density.",
      "typical": "A/G — intermediate HTR2A expression. Moderate serotonin receptor variation.",
      "concern": "A/A — increased HTR2A expression. Associated with altered serotonin signaling, increased anxiety sensitivity, and variable SSRI response. May benefit from pharmacogenomic-guided antidepressant selection."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4570625",
    "gene": "TPH2",
    "name": "Tryptophan Hydroxylase 2 / Serotonin Synthesis",
    "category": "mental_health",
    "description": "TPH2 is the rate-limiting enzyme for serotonin synthesis in the brain. The T allele is associated with reduced amygdala regulation, increased anxiety, and susceptibility to depression. Replicated in neuroimaging and psychiatric genetics studies.",
    "implications": {
      "beneficial": "G/G — normal TPH2 expression. Standard brain serotonin synthesis.",
      "typical": "G/T — one variant allele. Mildly altered serotonin synthesis. May have increased emotional reactivity.",
      "concern": "T/T — reduced TPH2 expression. Lower brain serotonin synthesis. Increased anxiety and depression susceptibility. Regular exercise and stress management particularly beneficial."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs27072",
    "gene": "SLC6A3 (DAT1)",
    "name": "Dopamine Transporter (DAT1)",
    "category": "mental_health",
    "description": "SLC6A3 encodes the dopamine transporter which clears dopamine from the synapse. The G allele is associated with increased DAT expression (faster dopamine clearance, lower synaptic dopamine), linked to ADHD susceptibility.",
    "implications": {
      "beneficial": "C/C — lower DAT expression. Standard synaptic dopamine levels.",
      "typical": "C/G — intermediate DAT expression. Moderate dopamine clearance.",
      "concern": "G/G — higher DAT expression. Faster dopamine clearance. Associated with ADHD traits and stimulant medication response."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3736228",
    "gene": "LRP5",
    "name": "Bone Mineral Density (LRP5 A1330V)",
    "category": "bone_health",
    "description": "LRP5 is essential for Wnt signaling in osteoblasts and is the strongest single-gene determinant of bone mineral density. The T allele reduces Wnt signaling and is associated with lower BMD and increased fracture risk. Replicated in GEFOS consortium GWAS (>80,000 individuals).",
    "implications": {
      "beneficial": "C/C (Ala/Ala) — normal LRP5 Wnt signaling. Standard bone mineral density.",
      "typical": "C/T — one Val allele. Mildly reduced BMD. Ensure adequate calcium, vitamin D, and weight-bearing exercise.",
      "concern": "T/T (Val/Val) — reduced Wnt signaling. Lower bone mineral density and ~1.5x fracture risk. DEXA scan recommended. Prioritize calcium, vitamin D, and resistance training."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1800012",
    "gene": "COL1A1",
    "name": "Collagen Type I Alpha 1 / Osteoporosis",
    "category": "bone_health",
    "description": "COL1A1 encodes the major structural protein in bone. The Sp1 binding site polymorphism alters the collagen alpha1/alpha2 ratio, weakening bone structure. Associated with reduced BMD, vertebral fractures, and osteoporosis.",
    "implications": {
      "beneficial": "G/G — normal collagen ratio. Standard bone structural integrity.",
      "typical": "G/T — heterozygous. Mildly altered collagen ratio. Slightly increased fracture risk.",
      "concern": "T/T — significantly altered collagen ratio. Increased osteoporosis and vertebral fracture risk. Bone density screening recommended."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1065852",
    "gene": "CYP2D6",
    "name": "Drug Metabolism / CYP2D6 (C100T)",
    "category": "pharmacogenomics",
    "description": "CYP2D6 metabolizes ~25% of all prescription drugs including codeine, tamoxifen, antidepressants, beta-blockers, and antipsychotics. Poor metabolizers cannot activate codeine to morphine and may not benefit from tamoxifen.",
    "implications": {
      "beneficial": "C/C — normal CYP2D6 activity. Standard drug metabolism for CYP2D6 substrates.",
      "typical": "C/T — intermediate metabolizer. May need dose adjustments for some CYP2D6 substrates.",
      "concern": "T/T — reduced CYP2D6 activity. Codeine may be ineffective. Tamoxifen activation impaired. Pharmacogenomic testing recommended before CYP2D6-dependent drugs."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4148323",
    "gene": "UGT1A1",
    "name": "Bilirubin Conjugation / Gilbert Syndrome (G71R)",
    "category": "pharmacogenomics",
    "description": "UGT1A1 conjugates bilirubin for excretion. The A allele reduces enzyme activity, causing Gilbert syndrome (benign unconjugated hyperbilirubinemia). Also affects metabolism of irinotecan (chemo) and atazanavir (HIV).",
    "implications": {
      "beneficial": "G/G — normal UGT1A1 activity. Standard bilirubin conjugation.",
      "typical": "G/A — carrier. Mildly elevated bilirubin. Usually asymptomatic.",
      "concern": "A/A — reduced UGT1A1 activity. Gilbert syndrome likely. Usually benign but critical for irinotecan dosing (severe toxicity risk). Inform oncologist if undergoing chemotherapy."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs9923231",
    "gene": "VKORC1",
    "name": "Warfarin Sensitivity / VKORC1",
    "category": "pharmacogenomics",
    "description": "VKORC1 is the target enzyme of warfarin. This promoter variant is the strongest genetic determinant of warfarin dose, explaining ~25% of dose variability. The T allele reduces VKORC1 expression, requiring lower warfarin doses. FDA-approved pharmacogenomic dosing label.",
    "implications": {
      "beneficial": "G/G — normal VKORC1 expression. Standard warfarin dose likely (~5-7 mg/day).",
      "typical": "G/T — intermediate VKORC1 expression. Moderate warfarin sensitivity (~3-5 mg/day typical).",
      "concern": "T/T — low VKORC1 expression. High warfarin sensitivity (~1-3 mg/day). Over-anticoagulation and bleeding risk at standard doses. Pharmacogenomic dosing strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1799853",
    "gene": "CYP2C9",
    "name": "Drug Metabolism / CYP2C9 (*2)",
    "category": "pharmacogenomics",
    "description": "CYP2C9 metabolizes ~15% of prescription drugs including warfarin, phenytoin, NSAIDs, and losartan. The *2 allele reduces enzyme activity ~30%. Combined with VKORC1, explains ~50% of warfarin dose variability. FDA pharmacogenomic dosing label.",
    "implications": {
      "beneficial": "C/C — normal CYP2C9 activity (*1/*1). Standard drug metabolism.",
      "typical": "C/T — CYP2C9 *1/*2 intermediate metabolizer. ~30% reduced activity. Consider lower starting doses for warfarin, NSAIDs.",
      "concern": "T/T — CYP2C9 *2/*2 poor metabolizer. ~70% reduced activity. Significantly impaired warfarin, NSAID, and phenytoin metabolism. Pharmacogenomic dosing recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs61764370",
    "gene": "KRAS (3'UTR)",
    "name": "KRAS let-7 MicroRNA Binding Variant",
    "category": "tumor_suppression",
    "description": "This variant in the 3'UTR of KRAS disrupts a let-7 microRNA binding site, increasing KRAS expression. Associated with increased risk for non-small cell lung cancer, ovarian cancer, and triple-negative breast cancer. Particularly relevant for never-smokers with lung cancer.",
    "implications": {
      "beneficial": "T/T — normal let-7 regulation of KRAS. Standard cancer risk baseline.",
      "concern": "G/T — one variant allele. Increased KRAS expression. ~1.3x lung and ovarian cancer risk. Follow standard screening guidelines closely.",
      "major_concern": "G/G — significantly increased KRAS expression. Enhanced screening consideration, especially with family history of lung or ovarian cancer."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "concern"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs2180439",
    "gene": "20p11.22",
    "name": "Male Pattern Baldness Risk (20p11)",
    "category": "hair",
    "description": "This locus on chromosome 20p11 is one of the strongest non-X-linked genetic contributors to androgenetic alopecia (male pattern baldness). The C allele increases baldness risk ~1.6x per copy. Unlike X-linked AR gene variants, this is autosomal and inherited from both parents.",
    "implications": {
      "beneficial": "T/T — lower genetic risk for androgenetic alopecia from this locus.",
      "typical": "C/T — one risk allele. Moderate genetic predisposition to hair loss.",
      "concern": "C/C — two risk alleles. ~2.5x increased androgenetic alopecia risk. Consider early intervention if hair thinning begins."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs7598759",
    "gene": "GRM7",
    "name": "Age-Related Hearing Loss (GRM7)",
    "category": "hearing",
    "description": "GRM7 encodes metabotropic glutamate receptor 7, which protects cochlear hair cells from glutamate excitotoxicity. Variants are associated with age-related hearing loss (presbycusis). The risk allele impairs neuroprotective glutamate signaling in the cochlea.",
    "implications": {
      "beneficial": "A/A — standard GRM7 function. Normal cochlear neuroprotection.",
      "typical": "A/G — one risk allele. Mildly increased susceptibility to age-related hearing loss.",
      "concern": "G/G — reduced GRM7 neuroprotection. Elevated presbycusis risk. Limit loud noise exposure, use ear protection, and get audiometric screening after age 50."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs6746030",
    "gene": "SCN9A",
    "name": "Pain Sensitivity (SCN9A)",
    "category": "pain",
    "description": "SCN9A encodes the Nav1.7 sodium channel in pain-sensing neurons. Rare loss-of-function mutations cause complete insensitivity to pain; gain-of-function mutations cause severe pain disorders. The A allele is associated with increased pain sensitivity.",
    "implications": {
      "beneficial": "G/G — standard SCN9A function. Typical pain sensitivity.",
      "typical": "A/G — one variant allele. Mildly increased pain perception.",
      "concern": "A/A — increased Nav1.7 channel activity. Heightened pain sensitivity. May require adjusted analgesic approaches."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs11591147",
    "gene": "PCSK9",
    "name": "PCSK9 Loss-of-Function (R46L)",
    "category": "cardiovascular",
    "description": "PCSK9 degrades LDL receptors, raising LDL cholesterol. The T allele (Leu46) is a loss-of-function variant that lowers lifetime LDL by ~15% and reduces coronary heart disease risk by ~47%. This natural experiment inspired the PCSK9 inhibitor drug class.",
    "implications": {
      "beneficial": "Carrier of PCSK9 loss-of-function (G/T or T/T). Lower lifetime LDL cholesterol and significantly reduced coronary heart disease risk (~47%).",
      "typical": "G/G — normal PCSK9 function. Standard LDL receptor turnover and cholesterol levels."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      }
    ]
  },
  {
    "rsid": "rs174547",
    "gene": "FADS1",
    "name": "Omega-3/6 Fatty Acid Desaturase",
    "category": "nutrient",
    "description": "FADS1 encodes delta-5 desaturase, the rate-limiting enzyme for converting plant-based ALA to EPA/DHA omega-3 fatty acids. The C allele has higher activity. The T allele reduces conversion, making dietary preformed EPA/DHA (fish oil) more important.",
    "implications": {
      "beneficial": "C/C — higher FADS1 activity. Efficient ALA-to-EPA/DHA conversion. Plant omega-3 sources more effective.",
      "typical": "C/T — intermediate desaturase activity. Moderate omega-3 conversion efficiency.",
      "concern": "T/T — lower FADS1 activity. Poor ALA-to-EPA/DHA conversion. Direct EPA/DHA supplementation (fish oil or algal oil) recommended over plant sources alone."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1205",
    "gene": "CRP",
    "name": "C-Reactive Protein Baseline Levels",
    "category": "inflammation",
    "description": "CRP is the most widely used clinical biomarker of systemic inflammation. This variant affects baseline CRP levels independent of inflammation status. Important for interpreting hsCRP blood tests — genetically low CRP may mask inflammation, while genetically high CRP may cause false alarm.",
    "implications": {
      "beneficial": "T/T — genetically lower baseline CRP. Favorable inflammatory profile, but hsCRP tests may underestimate true inflammation.",
      "typical": "C/T — intermediate baseline CRP levels.",
      "concern": "C/C — genetically higher baseline CRP. Elevated hsCRP on blood tests may partly reflect genetic tendency rather than active inflammation."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs10936599",
    "gene": "TERC",
    "name": "Telomere Length (TERC)",
    "category": "longevity",
    "description": "TERC encodes the RNA component of telomerase. Shorter telomeres are associated with cellular aging and age-related diseases. The C allele is associated with shorter leukocyte telomere length. Strongly replicated in the largest telomere GWAS meta-analyses.",
    "implications": {
      "beneficial": "T/T — associated with longer telomeres. Favorable cellular aging trajectory.",
      "typical": "C/T — intermediate telomere length.",
      "concern": "C/C — associated with shorter telomeres. Accelerated cellular aging. Exercise, stress management, adequate sleep, and Mediterranean diet support telomere maintenance."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4753426",
    "gene": "MTNR1B",
    "name": "Melatonin Receptor 1B / Sleep-Glucose Axis",
    "category": "sleep",
    "description": "MTNR1B encodes the melatonin receptor MT2, linking circadian rhythm to insulin secretion. The C allele increases receptor expression, impairing glucose-stimulated insulin release — explaining why late eating disproportionately affects glucose tolerance in carriers.",
    "implications": {
      "beneficial": "T/T — normal melatonin receptor expression. Standard circadian insulin coupling.",
      "typical": "C/T — one variant allele. Mildly altered melatonin-insulin coupling. Avoid very late eating.",
      "concern": "C/C — increased MTNR1B expression. Impaired nighttime glucose handling. Higher fasting glucose and T2D risk. Avoid late-night eating and maintain consistent sleep schedule."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3894194",
    "gene": "TYK2",
    "name": "Psoriasis & Autoimmune Skin Risk (TYK2)",
    "category": "skin",
    "description": "TYK2 encodes tyrosine kinase 2 in the JAK-STAT signaling pathway. Variants affect risk for psoriasis, psoriatic arthritis, and other autoimmune conditions. TYK2 is now a therapeutic target — deucravacitinib selectively inhibits TYK2 for psoriasis treatment.",
    "implications": {
      "beneficial": "G/G — lower TYK2-mediated autoimmune skin disease risk.",
      "typical": "G/T — one risk allele. Mildly elevated psoriasis susceptibility.",
      "concern": "T/T — elevated psoriasis and autoimmune skin risk. If symptomatic, TYK2 inhibitors may be particularly effective."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs11209026",
    "gene": "IL23R",
    "name": "IL-23 Receptor / Psoriasis & IBD Protection (R381Q)",
    "category": "skin",
    "description": "IL23R encodes the IL-23 receptor, a key driver of Th17-mediated inflammation in psoriasis, Crohn's disease, and ankylosing spondylitis. The rare A allele is strongly protective (~2x reduced risk). IL-23 is the target of multiple biologic drugs.",
    "implications": {
      "beneficial": "G/A or A/A — carrier of protective allele. ~2x reduced psoriasis and inflammatory bowel disease risk.",
      "typical": "G/G — no protective variant. Standard baseline risk for Th17-mediated inflammatory conditions."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/A",
          "A/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      }
    ]
  },
  {
    "rsid": "rs2981582",
    "gene": "FGFR2",
    "name": "FGFR2 Breast Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "FGFR2 (Fibroblast Growth Factor Receptor 2) is one of the strongest and most replicated breast cancer GWAS loci. The T allele increases ER-positive breast cancer risk ~1.26x per copy. Stronger association with estrogen receptor-positive disease.",
    "implications": {
      "beneficial": "C/C — lower genetic risk for breast cancer at this locus.",
      "typical": "C/T — one risk allele. Mildly elevated breast cancer risk (~1.26x).",
      "concern": "T/T — two risk alleles. ~1.63x increased breast cancer risk, particularly ER-positive subtypes."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3803662",
    "gene": "TOX3",
    "name": "TOX3 Breast Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "TOX3 (TNRC9) at 16q12 is a well-replicated breast cancer susceptibility locus. The T allele correlates with lower TOX3 expression, increasing breast cancer risk ~1.20x per copy. Replicated across multiple populations.",
    "implications": {
      "beneficial": "C/C — lower genetic risk at this locus.",
      "typical": "C/T — one risk allele. Modestly increased breast cancer risk (~1.20x).",
      "concern": "T/T — two risk alleles. ~1.40x increased breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs889312",
    "gene": "MAP3K1",
    "name": "MAP3K1 Breast Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "MAP3K1 at 5q11 encodes a MAPK kinase involved in cell proliferation signaling. The C allele is associated with modestly increased breast cancer risk (~1.13x per copy).",
    "implications": {
      "beneficial": "A/A — lower genetic risk at this locus.",
      "typical": "A/C — one risk allele. Mildly increased breast cancer risk.",
      "concern": "C/C — two risk alleles. ~1.22x increased breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs13387042",
    "gene": "2q35 intergenic",
    "name": "Chromosome 2q35 Breast Cancer Locus",
    "category": "cancer_breast",
    "description": "Intergenic variant at 2q35 with strong replication across European and Hispanic populations. The A allele increases breast cancer risk ~1.15x per copy.",
    "implications": {
      "beneficial": "G/G — lower genetic risk at this locus.",
      "typical": "A/G — one risk allele. Mildly increased breast cancer risk.",
      "concern": "A/A — two risk alleles. ~1.40x increased breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3817198",
    "gene": "LSP1",
    "name": "LSP1 Breast Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "LSP1 (Lymphocyte-Specific Protein 1) at 11p15. The C allele modestly increases breast cancer risk.",
    "implications": {
      "beneficial": "T/T — lower genetic risk at this locus.",
      "typical": "C/T — one risk allele. Small increase in breast cancer risk.",
      "concern": "C/C — two risk alleles. ~1.15x increased breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs10941679",
    "gene": "5p12/FGF10",
    "name": "5p12 ER-Positive Breast Cancer Locus",
    "category": "cancer_breast",
    "description": "Variant near FGF10/MRPS30 at 5p12. The G allele is associated with increased ER-positive breast cancer risk. Stronger effect in estrogen receptor-positive disease.",
    "implications": {
      "beneficial": "A/A — lower genetic risk at this locus.",
      "typical": "A/G — one risk allele. Modestly increased ER+ breast cancer risk.",
      "concern": "G/G — two risk alleles. ~1.30x increased ER-positive breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4973768",
    "gene": "SLC4A7",
    "name": "SLC4A7 Breast Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "SLC4A7 (Solute Carrier Family 4 Member 7) at 3p24. The T allele increases breast cancer risk ~1.11x per copy. Well-replicated in GWAS meta-analyses.",
    "implications": {
      "beneficial": "C/C — lower genetic risk at this locus.",
      "typical": "C/T — one risk allele. Small increase in breast cancer risk.",
      "concern": "T/T — two risk alleles. Modestly increased breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1045485",
    "gene": "CASP8",
    "name": "CASP8 Breast Cancer Protection (D302H)",
    "category": "cancer_breast",
    "description": "CASP8 (Caspase-8) D302H variant at 2q33. Unusual marker where the minor C allele is protective, reducing breast cancer risk in a dose-dependent manner (OR ~0.89 per C allele).",
    "implications": {
      "beneficial": "C/C — protective genotype. Reduced breast cancer risk (~0.74x).",
      "typical": "C/G — one protective allele. Modestly reduced breast cancer risk.",
      "concern": "G/G — common genotype. Standard baseline breast cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/G",
          "G/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "typical"
      }
    ]
  },
  {
    "rsid": "i4000377",
    "gene": "BRCA1",
    "name": "BRCA1 185delAG (Ashkenazi Founder)",
    "category": "cancer_breast",
    "description": "Ashkenazi Jewish founder mutation in BRCA1 (185delAG). FDA-approved 23andMe test. Carriers have ~72% lifetime breast cancer risk and ~44% ovarian cancer risk. High-penetrance pathogenic variant.",
    "implications": {
      "beneficial": "I/I — no deletion detected. Standard population-level risk.",
      "major_concern": "D/I — deletion carrier. Very high lifetime risk for breast and ovarian cancer. Genetic counseling strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "I/I"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "D/I",
          "I/D",
          "D/D"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "i4000378",
    "gene": "BRCA1",
    "name": "BRCA1 5382insC (Ashkenazi Founder)",
    "category": "cancer_breast",
    "description": "Ashkenazi Jewish founder mutation in BRCA1 (5382insC). FDA-approved 23andMe test. Carriers have substantially elevated lifetime breast and ovarian cancer risk. High-penetrance pathogenic variant.",
    "implications": {
      "beneficial": "I/I — no insertion detected. Standard population-level risk.",
      "major_concern": "D/I — insertion carrier. Very high lifetime risk for breast and ovarian cancer. Genetic counseling strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "I/I"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "D/I",
          "I/D",
          "D/D"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "i4000379",
    "gene": "BRCA2",
    "name": "BRCA2 6174delT (Ashkenazi Founder)",
    "category": "cancer_breast",
    "description": "Ashkenazi Jewish founder mutation in BRCA2 (6174delT). FDA-approved 23andMe test. Carriers have elevated lifetime risk for breast, ovarian, prostate, and pancreatic cancer. High-penetrance pathogenic variant.",
    "implications": {
      "beneficial": "I/I — no deletion detected. Standard population-level risk.",
      "major_concern": "D/I — deletion carrier. Elevated lifetime risk for breast, ovarian, prostate, and pancreatic cancer. Genetic counseling strongly recommended."
    },
    "rules": [
      {
        "genotypes": [
          "I/I"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "D/I",
          "I/D",
          "D/D"
        ],
        "status": "major_concern"
      }
    ]
  },
  {
    "rsid": "rs3814113",
    "gene": "BNC2",
    "name": "BNC2 Ovarian Cancer Susceptibility",
    "category": "cancer_breast",
    "description": "BNC2 at 9p22 is the strongest GWAS association for high-grade serous ovarian carcinoma. The C allele is protective, reducing ovarian cancer risk.",
    "implications": {
      "beneficial": "C/C — protective genotype. Reduced ovarian cancer risk.",
      "typical": "C/T — one protective allele. Modestly reduced ovarian cancer risk.",
      "concern": "T/T — standard risk genotype for high-grade serous ovarian cancer."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs6983267",
    "gene": "8q24/MYC region",
    "name": "8q24 Multi-Cancer Risk Locus",
    "category": "cancer_prostate",
    "description": "One of the most replicated multi-cancer variants at 8q24 near MYC. The G allele affects Wnt/TCF4 signaling and increases prostate cancer risk (~1.26x) and colorectal cancer risk (~1.50x). Population attributable risk ~21%.",
    "implications": {
      "beneficial": "T/T — lower genetic risk at this multi-cancer locus.",
      "typical": "G/T — one risk allele. Modestly increased prostate and colorectal cancer risk.",
      "concern": "G/G — two risk alleles. ~1.26x prostate, ~1.50x colorectal cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1447295",
    "gene": "8q24 (region 1)",
    "name": "8q24 Region 1 Prostate Cancer Locus",
    "category": "cancer_prostate",
    "description": "Independent 8q24 signal for prostate cancer risk. The A allele increases risk ~1.22x per copy. Population attributable risk ~9% for prostate cancer.",
    "implications": {
      "beneficial": "C/C — lower genetic risk at this locus.",
      "typical": "A/C — one risk allele. Modestly increased prostate cancer risk.",
      "concern": "A/A — two risk alleles. ~1.44x increased prostate cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs10993994",
    "gene": "MSMB",
    "name": "MSMB Prostate Cancer Susceptibility",
    "category": "cancer_prostate",
    "description": "MSMB (Microseminoprotein-Beta) at 10q11. The T risk allele downregulates MSMB expression by ~70%, increasing prostate cancer risk ~1.24x per copy.",
    "implications": {
      "beneficial": "C/C — normal MSMB expression. Lower prostate cancer risk.",
      "typical": "C/T — one risk allele. Reduced MSMB expression, modestly increased prostate cancer risk.",
      "concern": "T/T — significantly reduced MSMB expression (~70% lower). ~1.50x increased prostate cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4430796",
    "gene": "HNF1B",
    "name": "HNF1B Prostate & Endometrial Cancer",
    "category": "cancer_prostate",
    "description": "HNF1B (TCF2) at 17q12 is a pleiotropic locus also associated with type 2 diabetes. The A allele increases prostate cancer risk ~1.25x.",
    "implications": {
      "beneficial": "G/G — lower genetic risk at this locus.",
      "typical": "A/G — one risk allele. Modestly increased prostate cancer risk.",
      "concern": "A/A — two risk alleles. ~1.25x increased prostate cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1859962",
    "gene": "17q24.3",
    "name": "Chromosome 17q24 Prostate Cancer Locus",
    "category": "cancer_prostate",
    "description": "Variant at 17q24.3 associated with prostate cancer risk. The G allele increases risk ~1.37x for homozygous carriers.",
    "implications": {
      "beneficial": "T/T — lower genetic risk at this locus.",
      "typical": "G/T — one risk allele. Modestly increased prostate cancer risk.",
      "concern": "G/G — two risk alleles. ~1.37x increased prostate cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs16901979",
    "gene": "8q24 (region 2)",
    "name": "8q24 Region 2 Prostate Cancer Locus",
    "category": "cancer_prostate",
    "description": "Independent 8q24 signal from rs6983267 and rs1447295. The A allele increases prostate cancer risk ~1.47x.",
    "implications": {
      "beneficial": "C/C — lower genetic risk at this locus.",
      "typical": "A/C — one risk allele. Increased prostate cancer risk.",
      "concern": "A/A — two risk alleles. ~1.47x increased prostate cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4939827",
    "gene": "SMAD7",
    "name": "SMAD7 Colorectal Cancer Protection",
    "category": "cancer_colorectal",
    "description": "SMAD7 at 18q21 modulates TGF-β signaling. The T allele is protective, reducing colorectal cancer risk ~0.77x per copy. Stronger association with rectal than colon cancer.",
    "implications": {
      "beneficial": "T/T — protective genotype. Reduced colorectal cancer risk.",
      "typical": "C/T — one protective allele. Modestly reduced colorectal cancer risk.",
      "concern": "C/C — standard risk genotype for colorectal cancer."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs16892766",
    "gene": "EIF3H",
    "name": "EIF3H Colorectal Cancer Susceptibility",
    "category": "cancer_colorectal",
    "description": "EIF3H (Eukaryotic Translation Initiation Factor 3 Subunit H) at 8q23. The C risk allele increases colorectal cancer risk ~1.25x per copy.",
    "implications": {
      "beneficial": "A/A — lower genetic risk at this locus.",
      "typical": "A/C — one risk allele. Modestly increased colorectal cancer risk.",
      "concern": "C/C — two risk alleles. ~1.56x increased colorectal cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3802842",
    "gene": "11q23/LOC120376",
    "name": "Chromosome 11q23 Colorectal Cancer Locus",
    "category": "cancer_colorectal",
    "description": "Variant at 11q23 associated with colorectal cancer. The C allele increases risk, with stronger association for rectal cancer.",
    "implications": {
      "beneficial": "A/A — lower genetic risk at this locus.",
      "typical": "A/C — one risk allele. Modestly increased colorectal cancer risk.",
      "concern": "C/C — two risk alleles. ~1.35x increased colorectal cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "A/A"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/C",
          "C/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4779584",
    "gene": "GREM1",
    "name": "GREM1 Colorectal Cancer Susceptibility",
    "category": "cancer_colorectal",
    "description": "GREM1 (Gremlin 1) at 15q13 encodes a BMP antagonist involved in intestinal stem cell regulation. The T allele increases colorectal cancer risk ~1.26x per copy.",
    "implications": {
      "beneficial": "C/C — lower genetic risk at this locus.",
      "typical": "C/T — one risk allele. Modestly increased colorectal cancer risk.",
      "concern": "T/T — two risk alleles. Increased colorectal cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1805008",
    "gene": "MC1R",
    "name": "MC1R R160W Melanoma Risk",
    "category": "cancer_melanoma",
    "description": "MC1R R160W variant affects melanin switching. The T allele is associated with lighter pigmentation and increased melanoma risk (~1.5-2.0x). Weaker effect than MC1R R151C (rs1805007) but contributes to cumulative melanoma risk.",
    "implications": {
      "beneficial": "C/C — normal MC1R function at this position. Standard melanoma risk.",
      "typical": "C/T — one variant. Mildly increased UV sensitivity and melanoma risk.",
      "concern": "T/T — reduced MC1R function. Increased melanoma risk. Sun protection recommended."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1408799",
    "gene": "TYRP1",
    "name": "TYRP1 Melanoma Susceptibility",
    "category": "cancer_melanoma",
    "description": "TYRP1 (Tyrosinase-Related Protein 1) at 9p23 is involved in melanin biosynthesis. The T allele increases melanoma risk ~1.30x.",
    "implications": {
      "beneficial": "C/C — lower genetic risk for melanoma at this locus.",
      "typical": "C/T — one risk allele. Modestly increased melanoma risk.",
      "concern": "T/T — two risk alleles. ~1.30x increased melanoma risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1051730",
    "gene": "CHRNA3",
    "name": "CHRNA3 Lung Cancer & Nicotine Dependence",
    "category": "cancer_lung",
    "description": "CHRNA3 (Cholinergic Receptor Nicotinic Alpha 3) at 15q25. The T allele increases smoking intensity, carcinogen exposure per cigarette, and lung cancer risk ~1.30x per copy. Also associated with COPD.",
    "implications": {
      "beneficial": "C/C — lower genetic risk for lung cancer and nicotine dependence at this locus.",
      "typical": "C/T — one risk allele. Increased smoking intensity tendency and lung cancer risk (~1.30x).",
      "concern": "T/T — two risk alleles. ~1.60x lung cancer risk. Higher nicotine dependence. Smoking cessation especially important."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs16969968",
    "gene": "CHRNA5",
    "name": "CHRNA5 Lung Cancer & Nicotine Dependence (D398N)",
    "category": "cancer_lung",
    "description": "CHRNA5 (Cholinergic Receptor Nicotinic Alpha 5) at 15q25. The A allele (D398N) reduces the aversive effects of nicotine, promoting heavier smoking and increasing lung cancer risk. In strong LD with rs1051730. ~28% frequency in Europeans.",
    "implications": {
      "beneficial": "G/G — normal nicotinic receptor function. Lower genetic lung cancer risk.",
      "typical": "A/G — one risk allele. Reduced nicotine aversion, modestly increased lung cancer risk (~1.30x).",
      "concern": "A/A — two risk alleles. ~1.60x lung cancer risk. Significantly reduced nicotine aversion."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs8034191",
    "gene": "CHRNA3/5 region",
    "name": "CHRNA3/5 Region Lung Cancer Locus",
    "category": "cancer_lung",
    "description": "Independent signal in the CHRNA3/5 nicotinic receptor gene cluster at 15q25. The C allele increases lung cancer risk ~1.28x per copy.",
    "implications": {
      "beneficial": "T/T — lower genetic risk for lung cancer at this locus.",
      "typical": "C/T — one risk allele. Modestly increased lung cancer risk.",
      "concern": "C/C — two risk alleles. ~1.28x increased lung cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs1495741",
    "gene": "NAT2",
    "name": "NAT2 Slow Acetylator (Bladder Cancer)",
    "category": "cancer_bladder",
    "description": "NAT2 at 8p22 determines acetylation status. This tag SNP effectively classifies slow vs rapid acetylators. Slow acetylators (A/A) cannot efficiently detoxify aromatic amines, increasing bladder cancer risk ~1.46x. Especially relevant for smokers and occupational carcinogen exposure.",
    "implications": {
      "beneficial": "G/G — rapid acetylator. Efficient aromatic amine detoxification. Lower bladder cancer risk.",
      "typical": "A/G — intermediate acetylator. Moderately efficient detoxification.",
      "concern": "A/A — slow acetylator. Impaired detoxification of aromatic amines. ~1.46x bladder cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs9642880",
    "gene": "8q24",
    "name": "8q24 Bladder Cancer Locus",
    "category": "cancer_bladder",
    "description": "Variant at the 8q24 multi-cancer risk region specifically associated with bladder cancer. The G allele increases risk ~1.19x per copy.",
    "implications": {
      "beneficial": "T/T — lower genetic risk for bladder cancer at this locus.",
      "typical": "G/T — one risk allele. Modestly increased bladder cancer risk.",
      "concern": "G/G — two risk alleles. ~1.40x increased bladder cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "G/T",
          "T/G"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs710521",
    "gene": "TP63",
    "name": "TP63 Bladder Cancer Susceptibility",
    "category": "cancer_bladder",
    "description": "TP63 at 3q28 belongs to the p53 gene family and regulates epithelial development. The A allele increases bladder cancer risk ~1.37x for homozygous carriers.",
    "implications": {
      "beneficial": "G/G — lower genetic risk at this locus.",
      "typical": "A/G — one risk allele. Modestly increased bladder cancer risk.",
      "concern": "A/A — two risk alleles. ~1.37x increased bladder cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs505922",
    "gene": "ABO",
    "name": "ABO Blood Group Pancreatic Cancer Risk",
    "category": "cancer_digestive",
    "description": "ABO blood group locus at 9q34. The C allele (linked to non-O blood types) increases pancreatic cancer risk ~1.20x per copy. Blood type O is protective. Robustly replicated across diverse populations.",
    "implications": {
      "beneficial": "T/T — linked to blood type O. Lower pancreatic cancer risk.",
      "typical": "C/T — intermediate. Modestly increased pancreatic cancer risk.",
      "concern": "C/C — non-O blood type linkage. ~1.20x per allele increased pancreatic cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs3790844",
    "gene": "NR5A2",
    "name": "NR5A2 Pancreatic Cancer Protection",
    "category": "cancer_digestive",
    "description": "NR5A2 at 1q32 encodes a nuclear receptor that interacts with β-catenin pathway. The T allele is protective, reducing pancreatic cancer risk ~0.77x per copy.",
    "implications": {
      "beneficial": "T/T — protective genotype. Reduced pancreatic cancer risk.",
      "typical": "C/T — one protective allele. Modestly reduced pancreatic cancer risk.",
      "concern": "C/C — standard risk genotype for pancreatic cancer."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs4072037",
    "gene": "MUC1",
    "name": "MUC1 Gastric Cancer Susceptibility",
    "category": "cancer_digestive",
    "description": "MUC1 (Mucin 1) at 1q22 modulates promoter activity and alternative splicing. The G allele is protective against gastric cancer (OR ~0.70). Strongest association in Asian populations, also replicated in European cohorts.",
    "implications": {
      "beneficial": "G/G — protective genotype. Reduced gastric cancer risk.",
      "typical": "A/G — one protective allele. Modestly reduced gastric cancer risk.",
      "concern": "A/A — standard/higher risk genotype for gastric cancer."
    },
    "rules": [
      {
        "genotypes": [
          "G/G"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "A/G",
          "G/A"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "A/A"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2736100",
    "gene": "TERT",
    "name": "TERT Telomerase Multi-Cancer Variant",
    "category": "tumor_suppression",
    "description": "TERT (Telomerase Reverse Transcriptase) at 5p15. The C allele increases risk for lung, bladder, thyroid, and glioma (~1.39x), but is inversely associated with breast and colorectal cancer. Direction of effect varies by cancer type. Meta-analysis of 108,248 cases.",
    "implications": {
      "beneficial": "T/T — lower risk for lung/bladder/thyroid cancers (but may be slightly higher for breast/colorectal).",
      "typical": "C/T — intermediate. Mixed directional effects depending on cancer type.",
      "concern": "C/C — increased risk for lung, bladder, thyroid cancer, and glioma. Note: may be protective against breast/colorectal cancer."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs2279744",
    "gene": "MDM2",
    "name": "MDM2 SNP309 p53 Pathway Attenuator",
    "category": "tumor_suppression",
    "description": "MDM2 SNP309 at 12q15. The G allele increases MDM2 expression, attenuating the p53 tumor suppressor pathway. Associated with earlier cancer onset (~12 years earlier on average) across multiple cancer types including gastric, liver, colorectal, and gynecological cancers.",
    "implications": {
      "beneficial": "T/T — normal MDM2 expression. p53 pathway functions optimally.",
      "typical": "T/G — one risk allele. Moderately increased MDM2 expression. ~1.20x cancer risk.",
      "concern": "G/G — significantly increased MDM2 expression. Attenuated p53 pathway. ~1.54x cancer risk. Earlier age of onset."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "T/G",
          "G/T"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "G/G"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs17879961",
    "gene": "CHEK2",
    "name": "CHEK2 I157T DNA Damage Response",
    "category": "tumor_suppression",
    "description": "CHEK2 (Checkpoint Kinase 2) I157T at 22q12. This missense variant impairs CHEK2 binding to BRCA1 and p53, compromising DNA damage response. Increases breast cancer risk (~1.5-1.6x) and colorectal cancer risk (~1.6x). Higher penetrance for lobular breast cancer (OR ~4.17).",
    "implications": {
      "beneficial": "T/T — normal CHEK2 function. DNA damage checkpoint intact.",
      "typical": "C/T — one variant allele. Partially impaired CHEK2/BRCA1 binding. ~1.5x breast cancer risk.",
      "concern": "C/C — impaired CHEK2 function. Compromised DNA damage response. Enhanced screening recommended."
    },
    "rules": [
      {
        "genotypes": [
          "T/T"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "C/C"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs944289",
    "gene": "NKX2-1/PTCSC3",
    "name": "NKX2-1 Papillary Thyroid Cancer Risk",
    "category": "thyroid",
    "description": "NKX2-1 region at 14q13 regulates PTCSC3 long non-coding RNA tumor suppressor expression. The T allele increases papillary thyroid cancer risk ~1.60x for homozygous carriers.",
    "implications": {
      "beneficial": "C/C — lower genetic risk for papillary thyroid cancer.",
      "typical": "C/T — one risk allele. Modestly increased thyroid cancer risk.",
      "concern": "T/T — two risk alleles. ~1.60x increased papillary thyroid cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  },
  {
    "rsid": "rs966423",
    "gene": "DIRC3",
    "name": "DIRC3 Papillary Thyroid Cancer Risk",
    "category": "thyroid",
    "description": "DIRC3 (Disrupted in Renal Carcinoma 3) at 2q35. The T allele is associated with increased papillary thyroid cancer risk.",
    "implications": {
      "beneficial": "C/C — lower genetic risk for thyroid cancer at this locus.",
      "typical": "C/T — one risk allele. Modestly increased thyroid cancer risk.",
      "concern": "T/T — two risk alleles. Increased papillary thyroid cancer risk."
    },
    "rules": [
      {
        "genotypes": [
          "C/C"
        ],
        "status": "beneficial"
      },
      {
        "genotypes": [
          "C/T",
          "T/C"
        ],
        "status": "typical"
      },
      {
        "genotypes": [
          "T/T"
        ],
        "status": "concern"
      }
    ]
  }
]